...
首页> 外文期刊>Medical science monitor : >When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma
【24h】

When hepatic-side ductal margin is positive in N+ cases, additional resection of the bile duct is not necessary to render the negative hepatic-side ductal margin during surgery for extrahepatic distal bile duct carcinoma

机译:如果在N +病例中肝侧导管边缘为阳性,则在肝外远端胆管癌手术期间不必再切除胆管以使肝侧导管边缘阴性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Background The current standard treatment for extrahepatic distal bile duct carcinoma (EDBDC) is surgical resection, as no effective alternative treatment exists. In this study, we investigated the treatment strategies and outcomes for 90 cases of EDBDC at our department. Material and Methods Between April 2000 and March 2013, 90 pancreatoduodenectomies (PDs) were performed for EDBDC. The mean patient age was 69.1±9.8 years, and there were 59 males and 31 females. Extended lymph adenectomy including lymph nodes around the common hepatic artery and celiac axis was performed in all patients. The mean operation time was 537.1±153.8 min and the mean operative blood loss was 814.0±494.0 ml. There were no operation-related deaths. The overall 1-, 3-, and 5-year survival rates were 90.0%, 51.2%, and 45.0%, respectively. Results Lymph node metastasis was present in 28 patients (N+; 31.1%), and it was absent in 62 (N–; 68.9%). The 5-year survival rate was 20.0% for N+ patients and 52.4% for N– patients, which is significantly higher ([i]P[/i]=0.03).Nine cases (10.0%) showed hepatic-side ductal margin (HM) positivity for carcinoma. The 5-year survival rate was 18.7% for HM-positive patients and 48.3% for HM-negative patients, which is significantly higher ([i]P[/i]=0.005).In multivariate analysis, N+ was the strongest adverse prognostic factor.Subclass analysis of 62 cases (excluding 28 N+ cases) revealed 7 patients with positive HMs (11.3%) and 55 patients with negative HMs (88.7%). The 5-year survival rate was 47.6% for HM-positive patients and 49.8% for HM-negative patients ([i]P[/i]=0.73).Thirty-five cases (38.9%) recurred: there were 19 cases of local recurrence (21.1%), 11 cases of liver metastasis (12.2%), 4 cases of distant recurrence (4.4%), and 1 case of para-aortic lymph node metastasis (1.1%). Conclusions In conclusion, when HM is positive in N+ cases, additional resection of the bile duct is not necessary to render the HM negative for carcinoma.
机译:背景技术目前,肝外远端胆管癌(EDBDC)的标准治疗方法是手术切除,因为尚无有效的替代治疗方法。在这项研究中,我们调查了我科90例EDBDC的治疗策略和结果。材料和方法2000年4月至2013年3月,对EDBDC进行了90次胰十二指肠切除术(PD)。患者平均年龄为69.1±9.8岁,男59例,女31例。所有患者均进行了扩大的淋巴腺切除术,包括肝总动脉和腹腔轴周围的淋巴结。平均手术时间为537.1±153.8 min,平均手术失血量为814.0±494.0 ml。没有与手术有关的死亡。 1年,3年和5年总生存率分别为90.0%,51.2%和45.0%。结果28例患者有淋巴结转移(N +; 31.1%),而62例中无淋巴结转移(N–; 68.9%)。 N +患者的5年生存率是20.0%,N–患者的5年生存率是显着更高([i] P [/ i] = 0.03)。9例(10.0%)表现出肝侧导管切缘( HM)癌阳性。 HM阳性患者的5年生存率是18.7%,HM阴性患者的48.3%,这要高得多([i] P [/ i] = 0.005)。在多变量分析中,N +是最强的不良预后指标。对62例患者(不包括28个N +病例)进行亚类分析,发现7例HMs阳性(11.3%)和55例HMs阴性(88.7%)。 HM阳性患者的5年生存率为47.6%,HM阴性患者的49.8%([i] P [/ i] = 0.73)。35例(38.9%)复发:19例局部复发(21.1%),肝转移11例(12.2%),远处复发4例(4.4%)和主动脉旁淋巴结转移1例(1.1%)。结论总之,当N +病例中HM呈阳性时,不必额外切除胆管使HM阴性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号